Global Thalassaemia Review

Introduction

The first-ever TIF-developed Global Review of Thalassaemia is now a fact!

The Global Thalassaemia Review 2022 was put together by TIF, in collaboration with the World Health Organisation (WHO), as a collection of independent reports, to document the existing situation with thalassaemia across the world in the context of the various components of public health, clinical and social services, which are deemed essential for patients’ survival and wellbeing.

This video briefly introduces the Review’s key objectives and findings, highlighting the huge heterogeneity and inequality that people affected by thalassaemia still encounter in terms of access to quality healthcare services in many countries across the world.

Explore the Report

To improve clarity of presentation and facilitate readers, the Global Thalassaemia Review 2022 will be further divided into chapters in the following weeks.

Download

Infographics

The Global Thalassaemia Review’s Infographics underline the most substantial data on thalassaemia that this landmark report has exposed. They also summarize the key points of TIF’s call on national governments globally to safeguard the patients’ rights in health.

Availability

Blood insufficiency is experienced by more than 75% of patients in low- and middle- income countries.

Accessibility

More than 90% of the global patient population does not receive disease-specific social benefits.

Acceptability

Nationally coordinated and supported prevention programmes are absent in more than 80% of medium- and high- disease prevalence countries.

Quality

More than 60% of patients in low- and middle- income countries report recurring interruptions or postponements in their regular blood transfusions more than 15 times a year.

Progressive Realisation

In more than 90% of countries with medium- and high- disease prevalence, patients are still dependent on out of pocket expenses.

  • Availability

    Blood insufficiency is experienced by more than 75% of patients in low- and middle- income countries.

  • Accessibility

    More than 90% of the global patient population does not receive disease-specific social benefits.

  • Acceptability

    Nationally coordinated and supported prevention programmes are absent in more than 80% of medium- and high- disease prevalence countries.

  • Quality

    More than 60% of patients in low- and middle- income countries report recurring interruptions or postponements in their regular blood transfusions more than 15 times a year.

  • Progressive Realisation

    In more than 90% of countries with medium- and high- disease prevalence, patients are still dependent on out of pocket expenses.

Download

Download

Regional Profiles

Αfrica (AFR)

Αfrica (AFR)
Europe (ΕΜR)

Europe (ΕΜR)
Americas (AMR)

Americas (AMR)
Southeast Asia (SEAR)

Southeast Asia
(SEAR)
Eastern Mediterranean (EMR)

Eastern Mediterranean (EMR)
Western Pacific (WPR)

Western Pacific (WPR)
The Regional Profiles will be launched soon.

Additional Material

WHO Director General Addresses the Global Thalassaemia Community

National Success Stories in the Prevention and Management of Thalassaemia

Milestones in Thalassaemia Treatment
 by Prof John Porter

Global Thalassaemia Review High-level Event: The Premiere

Back to top button